Skyrizi — Nutrient Associations & Health Patterns
Also known as: Risankizumab-rzaa
Drug Class: Biologic Immunosuppressant (IL-23 Inhibitor)
Biologic medication that selectively inhibits interleukin-23 (IL-23), used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease by targeting specific immune pathways. Only evidence-qualified catalog relationships are listed here. Other catalog entries remain unverified in this reference; absence from the list does not rule out other medication effects or interactions.
Medication and Nutrition Context
Only evidence-qualified catalog relationships are listed here. Other catalog entries remain unverified in this reference; absence from the list does not rule out other medication effects or interactions.
Common Side Effects of Skyrizi
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
- Fungal infections
- TB reactivation risk
Key Drug Interactions — Skyrizi
Skyrizi has 3 documented drug-drug interactions in WePattern's Pattern Health Intelligence database. Key interactions include:
- Live vaccines (AVOID)
- Other immunosuppressants
- Immunizations
Frequently Asked Questions
What nutrient associations are reported for Skyrizi?
Only evidence-qualified catalog relationships are listed here. Other catalog entries remain unverified in this reference; absence from the list does not rule out other medication effects or interactions.
Which nutrient relationships are mapped for Skyrizi?
Only evidence-qualified catalog relationships are listed here. Other catalog entries remain unverified in this reference; absence from the list does not rule out other medication effects or interactions.
What are the side effects of Skyrizi?
Common side effects associated with Skyrizi include: Upper respiratory infections; Headache; Fatigue; Injection site reactions; Fungal infections.